CompletedPhase 1NCT03424603
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Studying Indolent B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sutro Biopharma, Inc.
- Principal Investigator
- Arturo Molina, MDSutro Biopharma
- Intervention
- STRO-001(drug)
- Enrollment
- 70 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2024
Study locations (22)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Arizona Oncology Associates, PC--HOPE Division, Tucson, Arizona, United States
- City of Hope Medical Center, Duarte, California, United States
- UC Davis Comprehensive Cancer Center, Sacramento, California, United States
- Univeristy of California San Francisco HDF Comprehensive Cancer Center, San Francisco, California, United States
- Rocky Mountain Cancer Center, Aurora, Colorado, United States
- Emory University Winship Cancer Institute, Atlanta, Georgia, United States
- Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
- University of Kansas Cancer Center, Fairway, Kansas, United States
- University of Maryland Medical Center, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Henry Ford Cancer Institute, Detroit, Michigan, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Weill Cornell Medicine, New York, New York, United States
- Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03424603 on ClinicalTrials.govOther trials for Indolent B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07166419Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic LeukemiaOhio State University Comprehensive Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07098364ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell LymphomaFred Hutchinson Cancer Center
- RECRUITINGPHASE1NCT06824701Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin LymphomaUniversity of Utah
- RECRUITINGPHASE2NCT07030699A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell LymphomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT07029217A Study of Reduced Dose Radiation Therapy for People With B-Cell LymphomasMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT06458439Epcoritamab-CAR T Cells for Large B-cell LymphomasAbramson Cancer Center at Penn Medicine
- RECRUITINGPHASE2NCT06442475Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06386315Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin LymphomaMayo Clinic